People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

compounded semaglutide comes in various concentrations. Reports received by the FDA found that healthcare providers have often miscalculated doses when converting from milligrams to units or ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

At baseline, a physical examination and laboratory tests were conducted. An eleven-week semaglutide drug dose titration period was started, and during this period, all participants continued using ...

New study reveals semaglutide ... and high or low dosage of medication. The likelihood of achieving 10% or more weight loss at one year was 2% higher for every unit increase in baseline BMI.

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...